Overall, as with actinium-radiolabeled somatostatin analogs in the treatment of neuroendocrine tumors, the promising early results of targeted alpha therapy with PSMA ligands suggest that the conclusions of prospective randomized trials comparing [225Ac]Ac-PSMA-617 or PSMA-I&T with current standard treatment options will be of great clinical importance. The gene discussed is FOLH1; the disease is neuroendocrine neoplasm.